BROOMFIELD, Colo. - (Business Wire) ARCA biopharma, Inc. (NASDAQ: ABIO), a biopharmaceutical company developing genetically targeted therapies for heart failure and other cardiovascular disease, today announced, as required by NASDAQ Marketplace Rule ...
[Published Mar 11 2010 by Earthtimes.org]